Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.
about
Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccineInnate immune sensing of DNA virusesImmunostimulatory Gene Therapy Using Oncolytic Viruses as VehiclesToll-like receptors: key players in antiviral immunityCircumventing antivector immunity: potential use of nonhuman adenoviral vectorsAdenovirus vectors for gene therapy, vaccination and cancer gene therapyTolerance and Cross-Tolerance following Toll-Like Receptor (TLR)-4 and -9 Activation Are Mediated by IRAK-M and Modulated by IL-7 in Murine SplenocytesKey role of splenic myeloid DCs in the IFN-alphabeta response to adenoviruses in vivoSheep lung segmental delivery strategy demonstrates adenovirus priming of local lung responses to bacterial LPS and the role of elafin as a response modulatorToll-Like Receptors and Viruses: Induction of Innate Antiviral Immune ResponsesPre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutininAdenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetNew pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors.Viral capsid is a pathogen-associated molecular pattern in adenovirus keratitisThe influence of innate and pre-existing immunity on adenovirus therapyTransduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle.The early activation of CD8+ T cells is dependent on type I IFN signaling following intramuscular vaccination of adenovirus vector.Remission of diabetes by insulin gene therapy using a hepatocyte-specific and glucose-responsive synthetic promoterReplicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy.Direct evidence from single-cell analysis that human {alpha}-defensins block adenovirus uncoating to neutralize infection.Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNATRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses.Evaluation of signal transduction pathways after transient cutaneous adenoviral gene delivery.Innate immune recognition of viruses and viral vectors.MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus.Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.In Vivo Synthesis of Cyclic-di-GMP Using a Recombinant Adenovirus Preferentially Improves Adaptive Immune Responses against Extracellular Antigens.Type I interferons mediate the innate cytokine response to recombinant fowlpox virus but not the induction of plasmacytoid dendritic cell-dependent adaptive immunity.Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses.Toll-like receptor agonists: are they good adjuvants?Recognition of virus infection and innate host responses to viral gene therapy vectors.Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse modelInduction of type I interferon by adenovirus-encoded small RNAs.Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity.Viral pre-challenge increases central nervous system inflammation after intracranial interleukin-1β injection.The human adenovirus type 5 E1B 55 kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells.
P2860
Q21134724-EB3F3683-2F09-4C6A-AD11-7D4428D1C163Q24626598-510680B7-4F5C-43AA-B648-38408DDD530CQ26777403-99EADEE6-13B7-4775-AC8C-E05B0514DC75Q26865983-6C877364-7D66-4A81-B1BF-1D8518295792Q26995655-EB93B3EE-C12D-4757-9FF4-E7E1F13F48EBQ27001601-26C86A68-7798-40FD-898C-9817222699DDQ27302768-FA7F554F-EE57-463D-9198-C0642A46927CQ27318346-E18379B4-AB7B-4681-A802-2528D196A8E8Q27347215-64DFC3B7-B511-4EBE-8DDB-1028B9E7F375Q27487393-1058DCC7-B458-4BFB-917B-D2E41C155E64Q28731982-FB1DF052-902F-4AEF-99DC-04A32FEB23E3Q28744136-D05D5B65-64A1-4A2A-9850-E846A71F709BQ30226988-A145EE37-4369-47EF-A6AC-526504357B76Q30227194-B0D5327D-BB6E-4544-9827-19A34642A10BQ30365380-913C7760-563D-44CE-A3C0-004020841D11Q30382097-23A6F54B-6312-40E8-B49B-0EB7BC4C6006Q33380283-16D43DAC-A4EE-4EB4-8A56-22A512777134Q33564368-8B008755-5707-4AD2-8F59-EEFD64C07FDFQ33655401-7F12F09E-9FFA-44C3-AC03-F408F8DC9C90Q33713019-938F3E1D-2993-4FFA-A0A5-2D876932ECB4Q33757762-6F46E8DB-84B6-45BE-A02D-6BFDEE6343E1Q33759358-AEA89C46-A243-4829-A0DA-90F3986C134BQ33762986-8C0652D0-9615-44AB-B06B-F3B5B30B7116Q33769294-75658BE6-41F2-4C0E-8D99-FA61FEC98011Q33778828-79429A1F-6841-4AD4-B3EA-7999A1587901Q33785096-7F570D2D-9E37-4538-8E3E-8C544ADB9BAEQ33799990-9AF3719A-2CD7-42A6-891A-E188A2E47C5DQ33805229-ABF8DBF4-F96C-4591-B28F-C9F33D6E6787Q33832157-A64C86E5-56F5-41B7-B945-ED65493959BCQ33881920-ABD5455A-ADCD-4243-8617-A806663059F3Q33924419-3DB51AE4-CAB8-42DE-8728-E465DC21AAE3Q33990693-440EE18C-D692-4344-A397-BCABC1CB7E3CQ34048648-CDC9E440-3512-4C4B-91AA-4B57AAAB2BA3Q34067537-1168A481-CF21-428B-928A-24C546DDA85AQ34080884-6D7AADDF-43DE-4771-BB9D-D20015B5772AQ34153735-A950D7DD-3662-4303-8B83-CD48B62BD09CQ34182607-76BFBB6C-4899-499B-A6C3-F1F1AADFF2BBQ34262192-3FFBB868-4CF9-4BF7-A2BA-1EB4AC06F423Q34363001-F1EB524D-F3E5-44C4-BF1E-B7772D8B4E07Q34388476-28FD6ABE-DF0B-4C99-AB39-D898A2EA578F
P2860
Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Innate immune response to aden ...... ent and -independent pathways.
@ast
Innate immune response to aden ...... ent and -independent pathways.
@en
type
label
Innate immune response to aden ...... ent and -independent pathways.
@ast
Innate immune response to aden ...... ent and -independent pathways.
@en
prefLabel
Innate immune response to aden ...... ent and -independent pathways.
@ast
Innate immune response to aden ...... ent and -independent pathways.
@en
P2093
P2860
P356
P1433
P1476
Innate immune response to aden ...... ent and -independent pathways.
@en
P2093
Jiangao Zhu
Xiaopei Huang
Yiping Yang
P2860
P304
P356
10.1128/JVI.02192-06
P407
P577
2007-01-17T00:00:00Z